REGULATORY
J&J’s Lazcluze, Genmab’s Tivdak, and More Up for MHLW Panel Review on Feb. 27
By Sakura Kono February 14, 2025
A key health ministry advisory panel will discuss on February 27 whether to recommend approval for a throng of new medicines including Janssen Pharmaceutical’s (J&J) third-generation EGFR tyrosine kinase inhibitor lazertinib, known as Lazcluze overseas.The…

LATEST

February 14, 2025
The volume-based generic drug use rate exceeded 80% for the first time in all 47 Japanese prefectures in September last year, according to a monthly report published by the Japan Health Insurance Association (Kyokai Kenpo).In…
February 14, 2025
Astellas Pharma said on February 13 that the US FDA has approved a broader label for its complement C5 inhibitor Izervay (avacincaptad pegol), removing the drug’s dosing duration limit to provide greater flexibility with its…
February 14, 2025
1. Build a Strong Employer BrandFirst up, let’s talk about your employer brand. Think of it as your company’s personality and reputation. In Japan’s competitive pharmaceutical and medical device industry, it’s crucial to stand out. You need to showcase your…
By Ken Yoshino

In late January, a bill to amend the Pharmaceuticals and Medical Devices Act cleared key legislation review processes by the…

By Philip Carrigan

As CEO of Morunda, I had the privilege of interviewing Bill Schuster, Country Manager of Viatris in South Korea. Our conversation delved into the multifaceted nature of leadership in the healthcare industry, exploring challenges, successes, and the power of authenticity.A…

By Takashi Ebisawa

A Japanese health ministry panel on December 26 wrapped up its discussions on the next amendment of the Pharmaceuticals and…

Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…

By Ken Yoshino

Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…

For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…

A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…

A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…

Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…

By Yoshinori Sagehashi

The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…

NEWS CATEGORY

REGULATORY

BUSINESS

ORGANIZATION

ACADEMIA